Latest News
Editas Medicine, Inc.
- Editas Medicine, Inc. Estimates – LSE:0IFK
- Wells Fargo raises target for Editas Medicine stock from USD 4.00 to USD 6.00
- Editas Medicine announces poster presentations at ESGCT 33rd Annual Congress and investor conference participation
- Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
- Editas Medicine to present gene editing research at ESGCT congress By Investing.com
- Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift
- Editas Medicine gains nod for clinical trial of EDIT-401 in cardiovascular disease
- Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
- Editas Medicine receives approval to start EDIT-401 trial in Australia
- Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions
- Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)
- Editas Medicine gets approval to start first hu...
Headlines from the last 30 days, linking to the original publishers. See all market news →